PPD, Inc. is launching the Vaccines & Biologics Center of Excellence, a network of integrated lab services focused on vaccine and biologic drug development. The center will offer comprehensive lab services to support development of products such as vaccines, monoclonal antibodies, peptides, protein-drug conjugates and other biologics. The integration of vaccine testing, bioanalytical, cGMP and global central lab services is designed to provide companies the opportunity to streamline and customize lab services for their biologics portfolios.

PPD has developed new technologies and assays to expand its vaccine testing services into the area of oncology vaccines, in addition to now having the capability to simultaneously provide testing for investigational pediatric and adolescent vaccine programs.

“With the industry’s largest collection of commercial vaccine assays and strong immunochemistry, cell culture and cGMP lab operations, PPD is the first CRO to offer the type of laboratory support that has the potential to bring significant efficiencies to the development of vaccines and biologics,” said Christine Dingivan, M.D., chief medical officer, PPD. “The Vaccines & Biologics Center of Excellence provides the high quality scientific support our clients are seeking in a way that allows them to bypass costly capital and resource investments necessary to develop and maintain these capabilities internally.”